Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy

Bromday (Bromfenac Ophthalmic Solution)0.09% QD vs Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Control of Pain and Epithelial Healing Post (PRK)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01475877

Enrollment

Registered

2011-11-21

Start date

2011-05-31

Completion date

2012-05-31

Last updated

2016-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Keywords

bromfenac, nepafenac, PRK, epithelial healing,

Brief summary

This study will compare the effect of two topical non-steroidal antiinflammatory agents to control pain after photorefractive keratectomy (PRK) eye surgery.

Interventions

DRUGBromfenac

Bromfenac 0.09% 1 drop in study eyes q day

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* male or female at least 18 years of age, * no other ocular studies with 15 days prior to dosing, * BCVA 20/200 or better, * return for study visits and follow instructions from investigator and staff, * self administer test article

Exclusion criteria

* Ocular inflammation, * hypersensitivity to bromfenac or nepafenac, * any corneal pathology, * have had radial keratotomy, * corneal transplant or corneal refractive surgery in the last two years

Design outcomes

Primary

Measure	Time frame
Post-PRK pain	7 days

Secondary

Measure	Time frame
Post-PRK epithelial healing	7 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026